Table 3 Univariate analysis for various clinical endpoints
Characteristic | N | OS(5-year) | p | DMFS(5-year) | p | RFS(5-year) | p value | PFS(5-year) | p |
|---|---|---|---|---|---|---|---|---|---|
Age(years) | 0.448 | 0.876 | 0.167 | 0.743 | |||||
≤41 | 100 | 72.3% | 66.8% | 85.3% | 59.0% | ||||
>41 | 98 | 66.2% | 64.4% | 93.0% | 60.4% | ||||
Gender | 0.451 | 0.691 | 0.312 | 0.665 | |||||
Male | 156 | 66.5% | 65.1% | 90.3% | 60.7% | ||||
Female | 42 | 78.1% | 66.4% | 84.7% | 54.9% | ||||
T stage | 0.018 | 0.048 | 0.514 | 0.070 | |||||
T1-2 | 71 | 75.1% | 72.1% | 93.3% | 66.2% | ||||
T3 | 95 | 70.9% | 67.2% | 87.0% | 61.0% | ||||
T4 | 32 | 48.6% | 43.4% | 86.5% | 39.4% | ||||
N stage | 0.145 | 0.125 | 0.785 | 0.401 | |||||
N2 | 172 | 71.0% | 67.9% | 88.9% | 61.1% | ||||
N3 | 26 | 55.7% | 50.1% | 91.3% | 50.1% | ||||
Histology | 0.735 | 0.944 | 0.821 | 0.844 | |||||
WHO I-II | 22 | 71.3% | 67.9% | 88.9% | 63.3% | ||||
WHO III | 176 | 68.6% | 65.2% | 89.1% | 59.1% | ||||
Treatment method | <0.001 | 0.018 | 0.004 | <0.001 | |||||
IMRT alone | 33 | 47.7% | 49.2% | 74.5% | 37.5% | ||||
Chemoradoitherapy | 165 | 73.1% | 68.5% | 91.3% | 63.8% |